| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Autologous CD34+-enriched hematopoietic stem and progenitor cells (Genenta Science) | Phase 2 Clinical | Genenta Science Srl | Carcinoma, Renal Cell; Glioblastoma; Multiple Myeloma | Details | |
| CX-801 | CX-801 | Phase 1 Clinical | Cytomx Therapeutics Inc | Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Melanoma | Details |
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Nadofaragene firadenovec | SCH-721015 | Approved | Schering - Plough Sa, Fkd Therapies | Adstiladrin | United States | Urinary Bladder Neoplasms | Ferring Pharmaceuticals A/S | 2022-12-16 | Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Mesothelioma | Details |

전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521
주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호



